Annals of Surgical Oncology

, Volume 5, Issue 4, pp 368–375

Competing causes of death for primary breast cancer

  • Edward B. Fish
  • Judy-Anne W. Chapman
  • Marilyn A. Link
Original Articles

Abstract

Background: A patient's likelihood of dying from breast cancer or another cause can be assessed with competing risks analyses.

Methods: Data for a cohort of 678 patients with primary invasive breast cancer accrued from 1971 to 1990, updated to 1995, included cause of death (e.g., breast cancer vs. other cause). We investigated the effects of age, tumor size, nodal status, ER, PgR, and adjuvant therapy (hormones, chemotherapy, radiotherapy) on type of death and time to death for patients of all ages and for those over the age of 65 years.

Results: Although there were no significant univariate differences in breast cancer death rates by age group (P=0.94), more patients over the age of 65 years died from other causes (41/207 [20%] of those older than 65 years vs. 16/471 [3%] of those younger than 65 years;P<.001). In competing risks analyses, older age was associated with non-breast cancer death, whereas larger tumor size was associated with breast cancer death. PgR was positively, and nodal status negatively, associated with survival, regardless of type. In the older patient group, the competing risks analyses identified similar effects for age and tumor size; in addition, higher ER assay values were less likely to be associated with breast cancer death.

Conclusions: With increased lifespan, there will be more breast cancer cases in women older than 65 years; we have shown that women in this group have more non-breast cancer deaths. It becomes important, then, to delineate differential effects of prognostic factors on competing causes of death.

Key Words

Breast cancer Elderly Competing causes of death 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Morrow M. Role of axillary dissection in breast cancer management.Ann Surg Oncol 1996;3:233–4.PubMedGoogle Scholar
  2. 2.
    Fish EB, Chapman JW, Link MA. Minimal surgery for breast cancer.Proceedings of the 16th International Cancer Congress, New Delhi, India. Bologna, Italy: Monduzzi Editore, 1994:1387–91.Google Scholar
  3. 3.
    Baxter N, McCready D, Chapman J, et al. The clinical behaviour of untreated axillary nodes following local treatment for primary breast cancer.Ann Surg Oncol 1996;3:235–40.PubMedGoogle Scholar
  4. 4.
    Fish EB, Chapman JW, Link MA. Discriminant analyses of minimal versus maximal surgery for breast cancer.Breast Cancer Res Treat 1994;32(suppl):69. Abstract.Google Scholar
  5. 5.
    Fish EB, Chapman JW, Link MA. Competing causes of death for primary breast cancer.Breast Cancer Res Treat 1996;37(suppl):54. Abstract.Google Scholar
  6. 6.
    Fish EB, Chapman JW, Link MA. Risks of regional recurrence with or without axillary dissection.Breast Cancer Res Treat 1996;41:274. Abstract.Google Scholar
  7. 7.
    Chapman JW, Fish EB, Link MA. Competing risks analysis for recurrence from primary breast cancer.Breast Cancer Res Treat 1996;37(suppl):57. Abstract.Google Scholar
  8. 8.
    Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women.Lancet 1992;339:1–15, 71–85.Google Scholar
  9. 9.
    Proschan F, Serfling RJ.Reliability and Biometry: Statistical Analysis of Lifelength. Philadelphia: Society for Industrial and Applied Mathematics, 1974.Google Scholar
  10. 10.
    Kalbfleisch JD, Prentice RL.The Statistical Analysis of Failure Time Data. New York: John Wiley and Sons, 1980:179–88.Google Scholar
  11. 11.
    Chapman JW, Hanna W, Kahn HJ, Lickley HLA, Wall J, Fish EB, McCready DR. Alternative multivariate modelling for time to local recurrence for breast cancer patients receiving a lumpectomy alone.Surg Oncol 1996;5:265–71.PubMedGoogle Scholar
  12. 12.
    Rutqvist LE, Wallgren A, Nilsson BO. Is breast cancer a curable disease?Cancer 1984;53:1793–1800.PubMedGoogle Scholar
  13. 13.
    Gamel JW, Vogel RL, Valaguisa P, Bonadonna G. Parametric survival analysis of adjuvant therapy for stage II breast cancer.Cancer 1994;74:2483–90.PubMedGoogle Scholar
  14. 14.
    Gamel JW, Meyer JS, Province MA. Proliferative rate by S-phase measurement may affect cure of breast carcinoma.Cancer 1995;76:1009–18.PubMedGoogle Scholar
  15. 15.
    Chapman JW, Mobbs BG, McCready DR, et al. An investigation of cut-points for primary breast cancer oestrogen and progesterone receptor assays.J Steroid Biochem Molec Biol 1996;57:323–8.PubMedGoogle Scholar
  16. 16.
    Chapman JW, Trudeau ME, Pritchard KI, et al. A comparison of all subset Cox and accelerated failure time models with Cox stepwise regression for node positive breast cancer.Breast Cancer Res Treat 1992;22:263–72.CrossRefPubMedGoogle Scholar
  17. 17.
    Fisher B, Redmond C, Fisher ER, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation.N Engl J Med 1985;312:674–81.PubMedGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 1998

Authors and Affiliations

  • Edward B. Fish
    • 1
  • Judy-Anne W. Chapman
    • 1
  • Marilyn A. Link
    • 1
  1. 1.Henrietta Banting Breast Centre, Women's College HospitalUniversity of TorontoTorontoCanada

Personalised recommendations